COTA’s Miruna Sasu: I left pharma to “turn the spigot on” in the real-world data industry

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Miruna Sasu spent more than 20 years as a digital health and innovation expert at life sciences companies—then came a realization:

“You can do all kinds of really cool technology things, but if you don’t have data, you can’t apply the technology; right?” Sasu said to The Cancer Letter. “Now that pharma companies can receive it and put it to good use, we want to turn the spigot on.”

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Matthew Bin Han Ong
Senior Editor
Table of Contents

YOU MAY BE INTERESTED IN

Patients treated with first-line immunotherapy for advanced non-small cell lung cancer showed similar results in terms of survival, progression-free survival, and treatment duration, regardless of race or ethnicity, even with differences in income and insurance, a study published in the Journal of the National Comprehensive Cancer Network showed.
Matthew Bin Han Ong
Senior Editor

Login